{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:56:04Z","timestamp":1777323364015,"version":"3.51.4"},"reference-count":82,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Despite prolonged viral inhibition with combination antiretroviral therapy (ART), HIV-1 survives as genetically intact, replication-capable proviruses within durable CD4+ T-cell fractions, involving central memory, transitional memory, and stem cell-like memory populations, as well as within tissue-resident compartments including lymphoid follicles and gut-associated lymphoid tissue. Reservoir stability is preserved via clonal growth of infected cells and epigenetic processes that impose proviral transcriptional silencing. As a result, current therapeutic approaches seek to either directly alter proviral survival or to improve immune-driven elimination of infected cells. At the molecular level, investigational strategies such as CRISPR\u2013Cas9 and CRISPR\u2013Cas12 gene-editing systems are intended to remove or induce inactivating mutations inside embedded proviral DNA, as well as alter host entrance co-receptors such as CCR5 to provide cellular resistance to infection. In addition, pharmacologic latency regulation is being studied via histone deacetylase inhibitors, protein kinase C agonists, and bromodomain inhibitors to reverse latency, along with Tat inhibitors and other transcriptional repressors aimed to persistently silence proviral expression. Moreover, immunological techniques aim to counteract inefficient endogenous antiviral defenses. Broadly neutralizing antibodies with tailored Fc-driven effector functions are under examination for both neutralization and antibody-dependent cellular cytotoxicity. Therapeutic vaccine approaches seek to elevate polyfunctional HIV-specific CD8+ T-cell responses, while adoptive cellular approaches, involving CAR-T cells aiming HIV envelope epitopes, remain in early clinical research. Immune checkpoint blockade is also being investigated to reverse T-cell depletion inside reservoir-rich tissues. Nevertheless, the key obstacles continue to be the diverse reservoir composition, restricted tissue penetration, viral escape, and safety limitations. The molecular and translational obstacles that characterize attempts toward an HIV cure must be addressed through ongoing multidisciplinary research.<\/jats:p>","DOI":"10.3390\/tropicalmed11050114","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:24:51Z","timestamp":1777317891000},"page":"114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Antiretroviral Therapy: Molecular and Immunological Innovations in HIV Treatment"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6750-4815","authenticated-orcid":false,"given":"Awadh","family":"Alanazi","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-5952","authenticated-orcid":false,"given":"Mohamed N.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories Sciences, College of Applied Medical Sciences at Al Qurayyat, Jouf University, Al Qurayyat 77454, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Elithy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Ain Shams University, Cairo 11544, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chou, T.C., Maggirwar, N.S., and Marsden, M.D. (2024). HIV Persistence, Latency, and Cure Approaches: Where Are We Now?. Viruses, 16.","DOI":"10.3390\/v16071163"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ye, F., Alvarez-Carbonell, D., Nguyen, K., Leskov, K., Garcia-Mesa, Y., Sreeram, S., Valadkhan, S., and Karn, J. (2022). Recruitment of the CoREST transcription repressor complexes by Nerve Growth factor IB-like receptor (Nurr1\/NR4A2) mediates silencing of HIV in microglial cells. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010110"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"198523","DOI":"10.1016\/j.virusres.2021.198523","article-title":"HIV-1 persistence in the CNS: Mechanisms of latency, pathogenesis and an update on eradication strategies","volume":"303","author":"Sonti","year":"2021","journal-title":"Virus Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/aid.2022.0180","article-title":"Viral Persistence in the Gut-Associated Lymphoid Tissue and Barriers to HIV Cure","volume":"40","author":"Cossarini","year":"2023","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106070","DOI":"10.1016\/j.ebiom.2025.106070","article-title":"PD-1 blockade enhances functional vaccine-induced HIV-1 CD8+ T-cell responses in PWH receiving early ART","volume":"123","author":"Marin","year":"2026","journal-title":"EBioMedicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41590-018-0085-3","article-title":"Resistance of HIV-infected macrophages to CD8+ T lymphocyte-mediated killing drives activation of the immune system","volume":"19","author":"Clayton","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-025-09893-0","article-title":"Sustained HIV-1 remission after heterozygous CCR5\u039432 stem cell transplantation","volume":"650","author":"Gaebler","year":"2026","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Matsuda, K., and Maeda, K. (2024). HIV reservoirs and treatment strategies toward curing HIV infection. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052621"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mohamed, H., Gurrola, T., Berman, R., Collins, M., Sariyer, I.K., Nonnemacher, M.R., and Wigdahl, B. (2022). Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.816515"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Xiao, Q., Guo, D., and Chen, S. (2019). Application of CRISPR\/Cas9-Based Gene Editing in HIV-1\/AIDS Therapy. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00069"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12977-021-00569-x","article-title":"Co-receptor signaling in the pathogenesis of neuroHIV","volume":"18","author":"Festa","year":"2021","journal-title":"Retrovirology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coviro.2019.07.011","article-title":"Targeting HIV-1 proviral transcription","volume":"38","author":"Olson","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41434-023-00410-4","article-title":"Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates","volume":"31","author":"Burdo","year":"2024","journal-title":"Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.molmed.2019.01.007","article-title":"Broadly Neutralizing Antibodies against HIV: Back to Blood","volume":"25","author":"Dashti","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COH.0000000000000742","article-title":"Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection","volume":"17","author":"Awan","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trsl.2020.04.008","article-title":"Therapeutic Vaccines for the Treatment of HIV","volume":"223","author":"Chen","year":"2020","journal-title":"Transl. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): A single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.chom.2022.07.013","article-title":"Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species","volume":"30","author":"Malouli","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., and Zhou, D. (2023). Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. Cancers, 15.","DOI":"10.3390\/cancers15133476"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Bardhi","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: A phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e150211","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eady6831","DOI":"10.1126\/scitranslmed.ady6831","article-title":"Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial","volume":"17","author":"Parks","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e185489","DOI":"10.1172\/JCI185489","article-title":"Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo","volume":"135","author":"Mu","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lewis, P.E., Poteet, E.C., Liu, D., Chen, C., LaBranche, C.C., Stanfield-Oakley, S.A., Montefiori, D.C., Ferrari, G., and Yao, Q. (2020). CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses. Vaccines, 8.","DOI":"10.3390\/vaccines8020284"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: A phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.scib.2025.01.002","article-title":"CAR-NK cell therapy: A potential antiviral platform","volume":"70","author":"Lin","year":"2025","journal-title":"Sci. Bull."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103840","DOI":"10.1016\/j.ebiom.2022.103840","article-title":"Immune checkpoint blockade in HIV","volume":"76","author":"Gubser","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2202148119","DOI":"10.1073\/pnas.2202148119","article-title":"PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques","volume":"119","author":"Velu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e184491","DOI":"10.1172\/jci.insight.184491","article-title":"IL-21 and anti-\u03b14\u03b27 dual therapy during ART promotes immunological and microbiome responses in SIV-infected macaques","volume":"10","author":"Johnson","year":"2025","journal-title":"JCI Insight"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Blanch-Lombarte, O., G\u00e1lvez, C., Revollo, B., Jim\u00e9nez-Moyano, E., Llibre, J.M., Manzano, J.L., Boada, A., Dalmau, J., Speiser, D.E., and Clotet, B. (2019). Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122089"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1038\/s41591-025-03993-0","article-title":"Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: A randomized, placebo-controlled phase 1b study","volume":"31","author":"Ramgopal","year":"2025","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31726","DOI":"10.1038\/s41598-025-15349-2","article-title":"Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites","volume":"15","author":"Guiraud","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/COH.0000000000000963","article-title":"CRISPR\/Cas9 for achieving postintervention HIV control","volume":"20","author":"Moso","year":"2025","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"110440","DOI":"10.1016\/j.jbc.2025.110440","article-title":"The role of chromatin in retroviral preintegration complex function","volume":"301","author":"Sapp","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0135821","DOI":"10.1128\/JVI.01358-21","article-title":"CRISPR\/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats","volume":"95","author":"Lai","year":"2021","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coviro.2019.07.001","article-title":"Elimination of infectious HIV DNA by CRISPR-Cas9","volume":"38","author":"Das","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Moretti, S., Virtuoso, S., Sernicola, L., Farcomeni, S., Maggiorella, M.T., and Borsetti, A. (2021). Advances in SIV\/SHIV non-human primate models of neuroAIDS. Pathogens, 10.","DOI":"10.3390\/pathogens10081018"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13072-024-00564-4","article-title":"The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: A comprehensive review","volume":"18","author":"Letchumanan","year":"2025","journal-title":"Epigenetics Chromatin"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s43141-022-00451-z","article-title":"Multiplexed shRNA-miRs as a candidate for anti HIV-1 therapy: Strategies, challenges, and future potential","volume":"20","author":"Jai","year":"2022","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114970","DOI":"10.1016\/j.addr.2023.114970","article-title":"Targeted delivery methods for RNA interference are necessary to obtain a potential functional cure for HIV\/AIDS","volume":"199","author":"Cisneros","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.omtn.2019.07.001","article-title":"Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy","volume":"17","author":"Takahashi","year":"2019","journal-title":"Molecular Therapy. Nucleic Acids"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Khatkar, P., Mensah, G., Ning, S., Cowen, M., Kim, Y., Williams, A., Abulwerdi, F.A., Zhao, Y., Zeng, C., and Le Grice, S.F.J. (2023). HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010033"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ahlenstiel, C.L., Symonds, G., Kent, S.J., and Kelleher, A.D. (2020). Block and Lock HIV Cure Strategies to Control the Latent Reservoir. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00424"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1038\/mtna.2013.64","article-title":"Promoter Targeting shRNA Suppresses HIV-1 Infection in vivo Through Transcriptional Gene Silencing","volume":"2","author":"Suzuki","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Agbosu, E.E., Ledger, S., Kelleher, A.D., Wen, J., and Ahlenstiel, C.L. (2022). Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071352"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2217887120","DOI":"10.1073\/pnas.2217887120","article-title":"CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice","volume":"120","author":"Dash","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.omtm.2022.01.012","article-title":"CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice","volume":"24","author":"Li","year":"2022","journal-title":"Molecular Therapy. Methods Clin. Dev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22555","DOI":"10.1038\/srep22555","article-title":"Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR\/Cas9 Gene Editing","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12977-022-00600-9","article-title":"Repression of HIV-1 reactivation mediated by CRISPR\/dCas9-KRAB in lymphoid and myeloid cell models","volume":"19","author":"Bomfim","year":"2022","journal-title":"Retrovirology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1128\/AAC.00949-15","article-title":"Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats","volume":"59","author":"Scarborough","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/s41467-025-60001-2","article-title":"Efficient mRNA delivery to resting T cells to reverse HIV latency","volume":"16","author":"Cevaal","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","article-title":"Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: Week 52 results of a phase 2\/3 trial","volume":"10","author":"Ogbuagu","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: Strategies to Eliminate Latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Covino, D.A., Desimio, M.G., and Doria, M. (2021). Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136654"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Vansant, G., Bruggemans, A., Janssens, J., and Debyser, Z. (2020). Block-And-Lock Strategies to Cure HIV Infection. Viruses, 12.","DOI":"10.3390\/v12010084"},{"key":"ref_61","first-page":"139","article-title":"Humanized mouse models for preclinical evaluation of HIV cure strategies","volume":"24","author":"Fraker","year":"2022","journal-title":"AIDS Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/jmv.25487","article-title":"Curaxin CBL0137 has the potential to reverse HIV-1 latency","volume":"91","author":"Jean","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Salahong, T., Schwartz, C., and Sungthong, R. (2021). Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?. Viruses, 13.","DOI":"10.3390\/v13061026"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: A first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Shaik","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/ajhp\/zxad223","article-title":"Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV","volume":"80","author":"Prather","year":"2023","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"34487","DOI":"10.1021\/jacs.5c08455","article-title":"Structural Basis for HIV-1 Maturation Inhibition by PF-46396 Determined by MAS NMR","volume":"147","author":"Zadorozhnyi","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Heidary, M., Shariati, S., Nourigheimasi, S., Khorami, M., Moradi, M., Motahar, M., Bahrami, P., Akrami, S., and Kaviar, V.H. (2024). Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09122-5"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Iacob, S.A., and Iacob, D.G. (2017). Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02323"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Thavarajah, J.J., H\u00f8nge, B.L., and Wejse, C.M. (2024). The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Viruses, 16.","DOI":"10.20944\/preprints202405.0383.v1"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Walsh, S.R., and Seaman, M.S. (2021). Broadly Neutralizing Antibodies for HIV-1 Prevention. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.712122"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Gruell","year":"2018","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: A phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zhang, C., Zaman, L.A., Poluektova, L.Y., Gorantla, S., Gendelman, H.E., and Dash, P.K. (2023). Humanized Mice for Studies of HIV-1 Persistence and Elimination. Pathogens, 12.","DOI":"10.3390\/pathogens12070879"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-020-01322-y","article-title":"Novel Approaches Towards a Functional Cure of HIV\/AIDS","volume":"80","author":"Bailon","year":"2020","journal-title":"Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hussein, M., Molina, M.A., Berkhout, B., and Herrera-Carrillo, E. (2023). A CRISPR-Cas Cure for HIV\/AIDS. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021563"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Dub\u00e9, K., Kanazawa, J., Patel, H., Louella, M., Sylla, L., Sheehy, J., Dee, L., Taylor, J., Adair, J., and Anthony-Gonda, K. (2022). Ethical and practical considerations for cell and gene therapy toward an HIV cure: Findings from a qualitative in-depth interview study in the United States. BMC Med. Ethics, 23.","DOI":"10.1186\/s12910-022-00780-1"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lindegger, D.J. (2024). Advanced Therapies for Human Immunodeficiency Virus. Med. Sci., 12.","DOI":"10.3390\/medsci12030033"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","article-title":"Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review","volume":"223","author":"Mahomed","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41590-022-01371-3","article-title":"Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4+ T cell reservoir","volume":"24","author":"Wu","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.tibtech.2020.10.010","article-title":"Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy","volume":"39","author":"Zeballos","year":"2021","journal-title":"Trends Biotechnol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.imj.2025.100215","article-title":"Beyond monotherapy: Combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management","volume":"2025","author":"Mao","year":"2025","journal-title":"Infect. Med."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/11\/5\/114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:19:25Z","timestamp":1777321165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/11\/5\/114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["tropicalmed11050114"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed11050114","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]}}}